SWS Partners’s Pacira BioSciences PCRX Stock Holding History

SWS Partners’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-9	Closed	–	–	406
2017 Q4	$0	Buy	+9	New	+$357	﹤0.01%	402

Other funds holding PCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

SWS Partners's PCRX Position: Q1 2018 in Review

SWS Partners sold out of Pacira BioSciences (PCRX) in Q1 2018, closing a stake of 9 shares.

SWS Partners first reported a position in PCRX in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 168 funds tracked by Wall St. Rank hold PCRX as of Q1 2018.

SWS Partners reported no remaining Pacira BioSciences position as of Q1 2018 after selling out during the quarter.
SWS Partners sold 9 Pacira BioSciences shares in Q1 2018.
SWS Partners first reported a position in Pacira BioSciences in Q4 2017 and held it in 1 quarter.
SWS Partners's Pacira BioSciences position peaked at $0 in Q4 2017.
168 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2018.

Based on SWS Partners's 13F filing for Q1 2018, filed 15 May 2018.